An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
Conditions
Interventions
- BIOLOGICAL: Opdivo
- BIOLOGICAL: Yervoy
Sponsor
Bristol-Myers Squibb